JPMorgan Increases Deal Size to $175M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
The deal size was increased to $175M from $150M and priced below last closing price of $14.60. JPMorgan, Leerink and Cantor Fitzgerald are acting as joint book running managers for the offering.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on FULC
Wall Street analysts forecast FULC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FULC is 16.80 USD with a low forecast of 7.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
1 Hold
1 Sell
Moderate Buy
Current: 10.480
Low
7.00
Averages
16.80
High
25.00
Current: 10.480
Low
7.00
Averages
16.80
High
25.00
About FULC
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BMO Initiates Medline Coverage with $45 Price Target
- Medline Coverage Initiation: BMO Capital analyst Sean Dodge initiated coverage on Medline Inc (NASDAQ:MDLN) with an Outperform rating and a price target of $45, indicating an approximate 11% upside from the current share price of $40.52, reflecting confidence in the company's growth prospects.
- Hims & Hers Rating Update: Evercore ISI Group analyst Mark Mahaney initiated coverage on Hims & Hers Health Inc (NYSE:HIMS) with an In-Line rating and a price target of $33, suggesting a stable growth outlook as the current share price stands at $31.69.
- Andersen Group Coverage Initiation: UBS analyst Kevin Mcveigh initiated coverage on Andersen Group Inc (NYSE:ANDG) with a Buy rating and a price target of $28, indicating significant upside potential from the current price of $24.29, reflecting optimism about its market performance.
- Netflix Rating Update: HSBC analyst Mohammed Khallouf initiated coverage on Netflix Inc (NASDAQ:NFLX) with a Buy rating and a price target of $107, suggesting an approximate 19% upside from the current share price of $89.44, indicating confidence in its content strategy and market position.
Continue Reading
Fulcrum Grants 30,400 Stock Options to New Employees at $10.84 Exercise Price
- Employee Incentive Program: Fulcrum Therapeutics granted 30,400 stock options to three new employees under its 2022 Inducement Stock Incentive Plan at an exercise price of $10.84 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the rare disease sector.
- Option Structure: The options have a ten-year term and vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly, ensuring continued employee contribution during their tenure, which enhances team stability and execution capability.
- Market Reaction: Fulcrum's stock closed at $10.84 on the grant date, reflecting the company's confidence in future growth while enhancing employee ownership and morale through incentive measures, which can boost overall productivity.
- Strategic Implications: This option grant is not only an incentive for new hires but also a critical move by Fulcrum to leverage talent attraction and retention strategies to drive innovation and business expansion in the rapidly evolving biopharmaceutical industry.
Continue Reading